About the Journal
|
Editorial Board
|
Instructions to Contributors
|
Submission & Review
|
Advertise with Us
|
Subscribe to E- Alerts
Sitemap
|
Feedback
Advanced search
Journal of Case Reports
Home
Online First
Current issue
Archives
ONLINE SUBMISSION
Contact Us
Urachal Adenocarcinoma Recurrence: A Case Report and Natural History of a Rare Disease
Himangsu Sarma
1
, Hariharan Ramesh
1
, Mahesh S Iyer
1
, Betcy Mary Babu
2
Departments of
1
Surgical Gastroenterology and
2
Pathology, Lakeshore Hospital and Research Centre, Kochi, Ernakulam, Kerala, India 682040.
Corresponding Author:
Dr Himangsu Sarma
Email: himangsu59@gmail.com
Received:
02-SEP-2025
Accepted:
09-DEC-2025
Published Online:
05-FEB-2026
DOI:
http://dx.doi.org/10.17659/01.2026.0003
Abstract
Background
: The urachus is an embryological remnant of the urogenital sinus and allantois. Urachal carcinoma is a rare, aggressive malignancy with limited literature, often diagnosed late and associated with poor prognosis and high recurrence and metastatic potential.
Case Presentation
: We report a 58-year-old woman who presented with gross hematuria and lower urinary tract symptoms. Imaging showed a solid-cystic mass at the dome of the urinary bladder. Cystoscopic biopsy confirmed mucinous adenocarcinoma of urachal origin. She underwent tumor resection with partial cystectomy. After three years, she developed recurrence and was managed with re-resection and multiple cycles of chemotherapy, with suboptimal response.
Conclusion
: This case highlights the aggressive natural history of urachal adenocarcinoma, emphasizing the importance of early diagnosis, complete surgical resection, vigilant follow-up, and the limited efficacy of chemotherapy in recurrent disease.
Keywords :
Carcinoma, Chemotherapy, Recurrence, Resection, Urachus.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Sarma H
Ramesh H
Iyer MS
Babu BM
Search Google Scholar for
Sarma H
Ramesh H
Iyer MS
Babu BM
Article Statistics
© 2011 Journal of Case Reports
Last updated on Mar 11, 2026